NDLI: Animal Models of Parkinson’s Disease: A Gateway to Therapeutics?

Content Provider	Springer Nature Link
Author	Le, Weidong Sayana, Pavani Jankovic, Joseph
Copyright Year	2013
Abstract	Parkinson’s disease (PD) is a progressive, neurodegenerative disorder of unknown etiology, although a complex interaction between environmental and genetic factors has been implicated as a pathogenic mechanism of selected neuronal loss. A better understanding of the etiology, pathogenesis, and molecular mechanisms underlying the disease process may be gained from research on animal models. While cell and tissue models are helpful in unraveling involved molecular pathways, animal models are much better suited to study the pathogenesis and potential treatment strategies. The animal models most relevant to PD include those generated by neurotoxic chemicals that selectively disrupt the catecholaminergic system such as 6-hydroxydopamine; 1-methyl-1,2,3,6-tetrahydropiridine; agricultural pesticide toxins, such as rotenone and paraquat; the ubiquitin proteasome system inhibitors; inflammatory modulators; and several genetically manipulated models, such as α-synuclein, DJ-1, PINK1, Parkin, and leucine-rich repeat kinase 2 transgenic or knock-out animals. Genetic and nongenetic animal models have their own unique advantages and limitations, which must be considered when they are employed in the study of pathogenesis or treatment approaches. This review provides a summary and a critical review of our current knowledge about various in vivo models of PD used to test novel therapeutic strategies.
Starting Page	92
Ending Page	110
Page Count	19
File Format	PDF
ISSN	19337213
Journal	NeuroRX
Volume Number	11
Issue Number	1
e-ISSN	18787479
Language	English
Publisher	Springer US
Publisher Date	2013-10-25
Publisher Institution	American Society for Experimental NeuroTherapeutics
Publisher Place	Boston
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Parkinson’s disease animal models neurotoxins transgenic motor symptoms non-motor symptoms therapeutics neuroprotection Neurosciences Neurology Neurosurgery Neurobiology
Content Type	Text
Resource Type	Article
Subject	Neurology (clinical) Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Protection against Parkinson’s disease progression: Clinical experience

Cell Therapeutics in Parkinson’s Disease

Treatment of Parkinson’s Disease: What’s in the Non-dopaminergic Pipeline?

Astrocytes and therapeutics for Parkinson’s disease

Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage (“Neuroprotection”)

Targeting Microvasculature for Neuroprotection after SCI

Novel therapeutics for Alzheimer’s disease

Translating therapies for Huntington’s disease from genetic animal models to clinical trials

Intrabodies as Neuroprotective Therapeutics

Animal Models of Parkinson’s Disease: A Gateway to Therapeutics?

Similar Documents

Protection against Parkinson’s disease progression: Clinical experience

Cell Therapeutics in Parkinson’s Disease

Treatment of Parkinson’s Disease: What’s in the Non-dopaminergic Pipeline?

Astrocytes and therapeutics for Parkinson’s disease

Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage (“Neuroprotection”)

Targeting Microvasculature for Neuroprotection after SCI

Novel therapeutics for Alzheimer’s disease

Translating therapies for Huntington’s disease from genetic animal models to clinical trials

Intrabodies as Neuroprotective Therapeutics

Animal Models of Parkinson’s Disease: A Gateway to Therapeutics?